Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients.

We have shown that systemic and cardiac sympathetic activation is present in heart failure with preserved ejection fraction (HFpEF) patients. Conversely, whereas systemic inflammatory activation was also detected in HFpEF, we did not detect local myocardial release of inflammatory cytokines. Activation of the sympathetic system correlated with both hemodynamic and demographic factors that characteristically cluster together in HFpEF. Together these data suggest that there may be a role for antiadrenergic therapies in certain HFpEF patients. The study does not implicate locally derived cytokines in the myocardial biology of HFpEF, although systemic sources may contribute to the global pathophysiology of HFpEF.
Competing Interests: This work was supported by a National Health & Medical Research Council (NHMRC) of Australia Fellowship support to Dr Kaye. Dr Marques is supported by a National Heart Foundation Future Leader Fellowship and National Heart Foundation Grants. The Baker Heart & Diabetes Institute is supported in part by the Victorian Government's Operational Infrastructure Support Program. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(© 2022 The Authors.)